BioSenic SA Stock price

Equities

BIOS

BE0974280126

Pharmaceuticals

Real-time Euronext Bruxelles 11:27:23 2024-03-28 am EDT 5-day change 1st Jan Change
0.0238 EUR +8.18% Intraday chart for BioSenic SA +6.25% -61.11%
Sales 2023 * - Sales 2024 * - Capitalization 4.04M 4.35M
Net income 2023 * -5M -5.39M Net income 2024 * -11M -11.86M EV / Sales 2023 * -
Net Debt 2023 * 18.8M 20.27M Net Debt 2024 * 29.3M 31.6M EV / Sales 2024 * -
P/E ratio 2023 *
-0.44 x
P/E ratio 2024 *
-0.24 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 68.53%
More Fundamentals * Assessed data
Dynamic Chart
Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease CI
BioSenic Raises Capital to Fund US FDA Application for Oral Arsenic Trioxide MT
BioSenic S.A. announced that it has received ?0.5 million in funding from Société Boursier.com SA, Gestys Sprl, Friedland Gestion CI
BioSenic Unit Wins Canadian Patent for Therapeutic Platform MT
BioSenic S.A. Patent Granted in Canada for Broader Protection of ATO Therapeutic Platform CI
BioSenic Presents New Phase 3 Data on JTA-004 to Treat Severe Osteoarthritis Pain at the 2024 OARSI World Congress CI
BioSenic Files US Patent for Osteoarthritis Therapy MT
BioSenic Files for Additional Patent Protection Following New Clinical Evidence of Efficacy for JTA-004 in OA CI
Biosenic: partnership with Phebra PTY evolves CF
BioSenic Signs Binding Term Sheet with Phebra for Oral Formulation Development of cGvHD Treatment MT
BioSenic Reaches Agreement on A Binding Term Sheet with Phebra PTY Ltd. with Respect to the Development of the First Oral Formulation of Arsenic Troxide for cGvHD Treatment CI
BioSenic Names Chief Scientific Officer as COO MT
Biosenic S.A. and Its Subsidiary Medsenic SAS Announces the Promotion of Carole Nicco to Chief Operating Officer CI
BioSenic S.A. announced that it expects to receive ?1.2 million in funding from Abo-Security S.R.L. CI
BioSenic S.A. announced that it expects to receive $9.6 million in funding CI
More news
1 day+8.18%
1 week+6.25%
Current month-23.23%
1 month-17.93%
3 months-60.98%
6 months-79.48%
Current year-61.11%
More quotes
1 week
0.02
Extreme 0.0204
0.02
1 month
0.01
Extreme 0.012
0.03
Current year
0.01
Extreme 0.012
0.07
1 year
0.01
Extreme 0.012
0.19
3 years
0.01
Extreme 0.012
0.35
5 years
0.01
Extreme 0.012
0.35
10 years
0.01
Extreme 0.012
0.35
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Chief Tech/Sci/R&D Officer - 23-04-02
Chief Operating Officer - 23-01-17
Members of the board TitleAgeSince
Director/Board Member - -
Director/Board Member 53 -
Chief Executive Officer - -
More insiders
Date Price Change Volume
24-03-28 0.0238 +8.18% 926 820
24-03-27 0.022 0.00% 1,767,569
24-03-26 0.022 0.00% 767,397
24-03-25 0.022 -1.79% 1,091,936
24-03-22 0.0224 0.00% 513,568

Real-time Euronext Bruxelles, March 28, 2024 at 06:31 am EDT

More quotes
BioSenic SA is a leading biotech company specializing in the development of clinical assets issued from the allogeneic cell therapy platform ALLOB and from the Arsenic TriOxide (ATO) platform. Key target indications for the platforms include Graft versus Host Disease (GvHD), Systemic lupus erythematosus (SLE), Systemic Sclerosis (SSc) and high-risk tibial fractures. Following the merger in October 2022, BioSenic SA combines the strategic positionings and strengths of Medsenic and Bone Therapeutics. The merger also enables Biosenic SA to add to its innovative cell therapy platform and strong IP for tissue repair protection with an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/OATO.
More about the company
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
0.022 EUR
Average target price
0.1 EUR
Spread / Average Target
+354.55%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock BioSenic SA - Euronext Bruxelles